Jiménez-Arredondo RE, Gutiérrez MJ, Solórzano GE, Chima GMC, Galaviz HC, García S, Di Silvio LM, Esparza R

Language: Spanish
References: 29
Page: 177-182
PDF size: 231.99 Kb.

ABSTRACT

Introduction: Refractory epilepsy represents almost 30% of all types of epilepsy. Polymorphisms and mutations in specific genes are related with the pathophysiology and response to treatment of epilepsy, particularly in its association with ion channels. Ion channels have functions as controlling and maintaining action potentials in cell membranes, so that mutations in genes encoding these channels are factors related with the refractory epilepsy.
Objective: To analyze the gene coding for the alpha subunit of the voltage-dependent sodium channel (SCN1A) in pediatric patients with refractory epilepsy, managed at the National Medical Center “20 de Noviembre”.
Methods: The molecular study was performed by analysis of exon 26 using end-point PCR and direct sequencing. The exon 26 was amplified in three fragments with the following primer pairs: 26a sense (AGG CTT CTG ACC ACT TTG AAC G), 26a antisense (TGT AGA TGT CAA TCA CCA CCA G), 26b sense (TGT GGG AAC CCA TGT GTT G), 26b antisense (CCA TGA ATC CCT CGA GCT TC), 26c sense (AAA TAC GCG TGC TTT GGT TC) and 26c antisense (GTT GTC GGG CAA TGA TGC AC).
Results: Molecular analysis identified 5 children (4 males, 1 female) with a nonsynonymous mutation in heterozygous state in exon 26: change from GAA (normal) to GCC in codon 1826 of SCN1A, replacing the glutamic acid (E) by alanine (A).
Conclusions: This study reports a non-conservative mutation which may be related to the lack of response to treatment in these patients, since the modification of the amino acid sequence can alter the physical and chemical characteristics and the three-dimensional structure of the alpha subunit of sodium channel, also altering its interaction with the beta subunit and as a consequence, possibly causing neuronal hyperexcitability. In Mexico do not know the prevalence of this mutation, however our invite hhalazgos confirm whether this genetic change is associated with refractory epilepsy. In Mexico do not know the prevalence of this mutation, however our findings warrant the confirmation whether this genetic change is associated with refractory epilepsy.

REFERENCES

1. Lares-Asseff I, Trujillo F. La farmacogenética y su importancia en la clínica. Gac Med Mex 2001; 137: 227-36.

2. Vogel F. Moderne probleme der humangenetik. Ergeb Inn Med Kinderheilkd 1959; 12: 52-125.

3. Garrod AE. Inborn errors of metabolism. London: Oxford University Press Reprint; 1963.

4. Motulsky AG. Drug reaction, enzymes and biochemical genetics. J Am Med Assoc 1957; 165: 835-7.

5. Vesell ES. Advances in pharmacogenetics. Prog Med Genet 1973; 9: 291-367.

6. Meyer UA. Genotype or Phenotype. The Definition of a Pharmacogenetic Polymorphism. Pharmacogenetics. 1991;1:66-7.

7. Vogel F, Motulsky AG. Human genetics, problems and approaches. New York: Springer ;1986, p. 435.

8. Lara TH. Análisis epidemiológico de la epilepsia en el INNN. 2000. XXV (4): 177-82

9. Guerrini R. Epilepsy in children. Lancet 2006; 367: 499-524.

10. Browne T, Holmes G. Epilepsy: Definitions and Background. Handbook of Epilepsy. 3rd. Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 1-20.

11. Engel J, Pedley TA. What is epilepsy? Epilepsy. Lippincott Williams & Wilkins; 1999.

12. Arzimanoglou A, Guerrini R, Aicardi J. Epilepsy: Overview and definitions. Aicardi’s epilepsy in children. 3rd. Ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004. p. 1-6.

13. Kwan P, et al. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 516: 1069-77.

14. Berg AT, Shinnar S, Levy SR, Testa FM, Smith-Rapaport S, Beckerman S. Early development of intractable epilepsy in children: a prospective study. Neurology 2001; 56: 1445-52.

15. Löscher W, Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. Journal of Pharmacology and Experimental Therapeutics 2002; 301: 7-14.

16. Arroyo S, et al. Is refractory epilepsy preventable? Epilepsia 2002; 43: 437-44.

17. Bazil CW. New antiepileptic drugs. Neurologist 2002; 8: 71-81.

18. Begley DJ. ABC Transporters and The Blood-Brain Barrier. Curr Pharm Design 2004; 10: 1295-312.

19. Remy S, et al. A novel mechanism underlying drug resistance in chronic epilepsy. Ann Neurol 2003; 53: 469-79.

20. Campos-Castelló J, Canelón M, García-Fernández M. Aspectos clínicos de las canalopatías epilépticas. Rev Neurol 2000; 30: S42- S46.

21. Meisler M, Kearney J. Sodium channel mutations in epilepsy and other neurological disorders. J Clin Invest 2005; 115: 2010-17.

22. Köhling R. Voltage-Gated Sodium Channels in Epilepsy. Epilepsia 2002; 43: 1278-95.

23. Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. World. Medical Association Declaration of Helsinki. Junio 1999; 42: 635-97.

24. Declaración internacional sobre los datos genéticos humanos. Octubre 2003. http://www.unesco.org

25. Kaneko S, et. al: Genetic Identifiers of epilepsy. Epilepsia, 2004, 43:16-20.

26. Hirose S, et al. Genetic of idiophatic epilepsies. Epilepsia 2005, 46: 38-43.

27. Schmidt D, et al. Drug resistence in epilepsy. Epilepsia 2005, 46: 858-77.

28. Kanai K, et al. Mutations in SCN1A and epilepsy phenotype severity. Neurology 2004, 63: 329-34.

29. Spampanaton S, et al. A novel epilepsy mutation in the sodium Channel SCN1a gene. J Neuroscience 2004; 24: 10022-34.